B-type natriuretic peptides: Looking to the future

References

• Wu AHB, Jaffe AS, Apple FS, Jesse RL, Francis GL, Morrow DA, . National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Use of cardiac troponin and B-type natriuretic peptide or N-terminal proB-type natriuretic peptide for etiologies other than acute coronary syndromes and heart failure. Clin Chem. 2007;53:2086–96.
   PubMed Web of Science ®Google Scholar
• Mueller C, Scholer A, Laule-Kilian K, Martina B, Schindler C, Buser P, . Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med. 2004;350:647–54.
   PubMed Web of Science ®Google Scholar
• Mueller C, Laule-Kilian K, Schindler C, Klima T, Frana B, Rodriguez D, . Cost-effectiveness of B-type natriuretic peptide testing in patients with acute dyspnea. Arch Intern Med. 2006;166:1081–7.
   PubMedGoogle Scholar
• Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, . Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002;347:161–7.
   PubMed Web of Science ®Google Scholar
• Siebert U, Januzzi JJL, Beinfeld MT, Cameron R, Gazelle GS. Cost-effectiveness of using N-terminal pro-brain natriuretic peptide to guide the diagnostic assessment and management of dyspneic patients in the emergency department. Am J Cardiol. 2006;98:800–5.
   PubMed Web of Science ®Google Scholar
• Moe GW, Howlett J, Januzzi JL, Zowall H; Canadian Multicenter Improved Management of Patients With Congestive Heart Failure Study I. N-terminal pro-B-type natriuretic peptide testing improves the management of patients with suspected acute heart failure: Primary results of the Canadian prospective randomized multicenter IMPROVE-CHF Study. Circulation. 2007;115:3103–10.
   PubMed Web of Science ®Google Scholar
• Wright SP, Doughty RN, Pearl A, Gamble GD, Whalley GA, Walsh HJ, . Plasma amino-terminal pro-brain natriuretic peptide and accuracy of heart-failure diagnosis in primary care: A randomized, controlled trial. J Am Coll Cardiol. 2003;42:1793–800.
   PubMed Web of Science ®Google Scholar
• Nielsen LS, Svanegaard J, Klitgaard NA, Egeblad H. N-terminal pro-brain natriuretic peptide for discriminating between cardiac and non-cardiac dyspnoea. Eur J Heart Fail. 2004;6:63–70.
   PubMed Web of Science ®Google Scholar
• Davis M, Espiner E, Richards G, Billings J, Town I, Neill A, . Plasma brain natriuretic peptide in assessment of acute dyspnoea. Lancet. 1994;343:440–4.
   PubMed Web of Science ®Google Scholar
• Wang CS, FitzGerald JM, Schulzer M, Mak E, Ayas NT. Does this dyspneic patient in the emergency department have congestive heart failure? JAMA. 2005;294:1944–56.
   PubMed Web of Science ®Google Scholar
• Mogelvang R, Goetze JP, Schnohr P, Lange P, Sogaard P, Rehfeld JF, . Discriminating between cardiac and pulmonary dysfunction in the general population with dyspnea by plasma pro-B-type natriuretic peptide. J Am Coll Cardiol. 2007;50:1694–701.
   PubMed Web of Science ®Google Scholar
• Rogers RK, Stoddard GJ, Greene T, Michaels AD, Fernandez G, Freeman A, . Usefulness of adjusting for clinical covariates to improve the ability of B-type natriuretic peptide to distinguish cardiac from noncardiac dyspnea. Am J Cardiol. 2009;104:689–94.
   Google Scholar
• Anderson JV, Woodruff PW, Bloom SR. The effect of treatment of congestive heart failure on plasma atrial natriuretic peptide concentration: a longitudinal study. Br Heart J. 1988;59:207–11.
   Google Scholar
• Stevenson LW, Dracup KA, Tillisch JH. Efficacy of medical therapy tailored for severe congestive heart failure in patients transferred for urgent cardiac transplantation. Am J Cardiol. 1989;63:461–4.
   PubMed Web of Science ®Google Scholar
• Steimle AE, Stevenson LW, Chelimsky-Fallick C, Fonarow GC, Hamilton MA, Moriguchi JD, . Sustained hemodynamic efficacy of therapy tailored to reduce filling pressures in survivors with advanced heart failure. Circulation. 1997;96:1165–72.
   PubMed Web of Science ®Google Scholar
• Murdoch DR, McDonagh TA, Byrne J, Blue L, Farmer R, Morton JJ, . Titration of vasodilator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration: Randomized comparison of the hemodynamic and neuroendocrine effects of tailored versus empirical therapy. Am Heart J. 1999;138:1126–32.
   PubMed Web of Science ®Google Scholar
• Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet. 2000;355:1126–30.
   PubMed Web of Science ®Google Scholar
• Felker GM, Hasselblad V, Hernandez AF, O’Connor CM. Biomarker-guided therapy in chronic heart failure: A meta-analysis of randomized controlled trials. Am Heart J. 2009;158:422–30.
   PubMed Web of Science ®Google Scholar
• Pfisterer M, Buser P, Rickli H, Gutmann M, Erne P, Rickenbacher P, . BNP-guided vs symptom-guided heart failure therapy: The trial of intensified vs standard medical therapy in elderly patients with congestive heart failure (TIME-CHF) Randomized Trial. JAMA. 2009;301:383–92.
   PubMed Web of Science ®Google Scholar
• Lainchbury JG, Troughton RW, Strangman KM, Frampton CM, Pilbrow A, Yandle TG, . N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) trial. J Am Coll Cardiol. 2010; 55:53–60.
   Google Scholar
• Kosiborod M, Lichtman JH, Heidenreich PA, Normand SL, Wang Y, Brass LM, . National trends in outcomes among elderly patients with heart failure. Am J Med. 2006;119:616.e1–16.e7.
   PubMed Web of Science ®Google Scholar
• Porapakkham P, Porapakkham P, Zimmet H, Billah B, Krum H. B-type natriuretic peptide-guided heart failure therapy: a meta-analysis. Arch Intern Med. 2010;170:507–14.
   PubMedGoogle Scholar
• Berger R, Moertl D, Peter S, Ahmadi R, Huelsmann M, Yamuti S, . N-terminal pro-B-type natriuretic peptide-guided, intensive patient management in addition to multidisciplinary care in chronic heart failure: A 3-arm, prospective, randomized pilot study. J Am Coll Cardiol. 2010;55:645–53.
   PubMed Web of Science ®Google Scholar
• Schou M, Gustafsson F, Videbaek L, Markenvard J, Ulriksen H, Ryde H, . Design and methodology of the NorthStar study: NT-proBNP stratified follow-up in outpatient heart failure clinics—A randomized Danish multicenter study. Am Heart J. 2008;156:649–55.
   Google Scholar
• Paterna S, Parrinello G, Cannizzaro S, Fasullo S, Torres D, Sarullo FM, . Medium term effects of different dosage of diuretic, sodium, and fluid administration on neurohormonal and clinical outcome in patients with recently compensated heart failure. Am J Cardiol. 2009;103:93–102.
   PubMed Web of Science ®Google Scholar
• Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, . Kidney disease as a risk factor for development of cardiovascular disease: A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation. 2003;108:2154–69.
   PubMed Web of Science ®Google Scholar
• Schiffrin EL, Lipman ML, Mann JFE. Chronic kidney disease: Effects on the cardiovascular system. Circulation. 2007; 116:85–97.
   PubMed Web of Science ®Google Scholar
• Dastoor H, Bernieh B, Boobes Y, Abouchacra S, Eltayeb E, Elhuda MN, . Plasma BNP in patients on maintenance haemodialysis: a guide to management? J Hypertens. 2005;23:23–8.
   Google Scholar
• Zoccali C, Mallamaci F, Benedetto FA, Tripepi G, Parlongo S, Cataliotti A, . Cardiac natriuretic peptides are related to left ventricular mass and function and predict mortality in dialysis patients. J Am Soc Nephrol. 2001;12:1508–15.
   PubMed Web of Science ®Google Scholar
• Gutierrez OM, Tamez H, Bhan I, Zazra J, Tonelli M, Wolf M, . N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentrations in hemodialysis patients: prognostic value of baseline and follow-up measurements. Clin Chem. 2008;54:1339–48.
   Google Scholar
• Di Angelantonio E, Chowdhury R, Sarwar N, Ray KK, Gobin R, Saleheen D, . B-type natriuretic peptides and cardiovascular risk: systematic review and meta-analysis of 40 prospective studies. Circulation. 2009;120:2177–87.
   PubMed Web of Science ®Google Scholar
• deFilippi CR, Christenson RH, Gottdiener JS, Kop WJ, Seliger SL. Dynamic cardiovascular risk assessment in elderly people: The role of repeated N-terminal pro-B-type natriuretic peptide testing. J Am Coll Cardiol. 2010; 55:441–50.
   PubMed Web of Science ®Google Scholar
• Struthers AD, Morris AD. Screening for and treating left-ventricular abnormalities in diabetes mellitus: a new way of reducing cardiac deaths. Lancet. 2002;359:1430–2.
   PubMed Web of Science ®Google Scholar
• Bhalla MA, Chiang A, Epshteyn VA, Kazanegra R, Bhalla V, Clopton P, . Prognostic role of B-type natriuretic peptide levels in patients with type 2 diabetes mellitus. J Am Coll Cardiol. 2004;44:1047–52.
   PubMed Web of Science ®Google Scholar
• Gæde P, Hildebrandt P, Hess G, Parving HH, Pedersen O. Plasma N-terminal pro-brain natriuretic peptide as a major risk marker for cardiovascular disease in patients with type 2 diabetes and microalbuminuria. Diabetologia. 2005;48: 156–63.
   PubMed Web of Science ®Google Scholar
• Betti I, Castelli G, Barchielli A, Beligni C, Boscherini V, De Luca L, . The role of N-terminal PRO-brain natriuretic peptide and echocardiography for screening asymptomatic left ventricular dysfunction in a population at high risk for heart failure. The PROBE-HF Study. J Card Fail. 2009; 15:377–84.
   PubMed Web of Science ®Google Scholar
• Andreadis EA, Georgiopoulos DX, Tzavara CK, Katsanou PM, Fragouli EG, Mavrokefalou EM, . Plasma brain natriuretic peptide: a biochemical marker of effective blood pressure management? J Hypertens. 2009;27:425–32.
   PubMed Web of Science ®Google Scholar
• Carr SJ, Bavanandan S, Fentum B, Ng L. Prognostic potential of brain natriuretic peptide (BNP) in predialysis chronic kidney disease patients. Clin Sci. 2005;109:75–82.
   PubMedGoogle Scholar
• Chrysohoou C, Greenberg M, Pitsavos C, Panagiotakos DB, Ladis V, Barbetseas J, . Diastolic function in young patients with beta-thalassemia major: An echocardiographic study. Echocardiography. 2006;23:38–44.
   Google Scholar
• Kremastinos DT, Hamodraka E, Parissis J, Tsiapras D, Dima K, Maisel A. Predictive value of B-type natriuretic peptides in detecting latent left ventricular diastolic dysfunction in β-thalassemia major. Am Heart J. 2010;159:68–74.
   Google Scholar
• Ribeiro ALP, dos Reis AM, Barros MVL, de Sousa MR, Rocha ALL, Perez AA, . Brain natriuretic peptide and left ventricular dysfunction in Chagas’ disease. Lancet. 2002;360:461–2.
   PubMed Web of Science ®Google Scholar
• Moreira MC, Wang Y, Heringer-Walther S, Wessel N, Walther T. Prognostic value of natriuretic peptides in Chagas’ disease: A head-to-head comparison of the 3 natriuretic peptides. Congest Heart Fail. 2009;15:75–81.
   PubMedGoogle Scholar
• Cuthbertson BH, Croal BL, Rae D, Gibson PH, McNeilly JD, Jeffrey RR, . N-terminal pro-B-type natriuretic peptide levels and early outcome after cardiac surgery: a prospective cohort study. Br J Anaesth. 2009;103:647–53.
   PubMed Web of Science ®Google Scholar
• Attaran S, Sherwood R, Desai J, Langworthy R, Mhandu P, John L, . Brain natriuretic peptide a predictive marker in cardiac surgery. Interact Cardiovasc Thorac Surg. 2009; 9:662–6.
   Google Scholar
• Karthikeyan G, Moncur RA, Levine O, Heels-Ansdell D, Chan MTV, Alonso-Coello P, . Is a pre-operative brain natriuretic peptide or N-terminal pro-B-type natriuretic peptide measurement an independent predictor of adverse cardiovascular outcomes within 30 days of noncardiac surgery? A systematic review and meta-analysis of observational studies. J Am Coll Cardiol. 2009;54:1599–606.
   PubMed Web of Science ®Google Scholar
• Choi J-H, Cho DK, Song Y-B, Hahn J-Y, Choi S, Gwon H-C, . Perioperative NT-proBNP and CRP predict perioperative major cardiovascular events in non-cardiac surgery. Heart. 2010;96:56–62.
   PubMed Web of Science ®Google Scholar
• Gill D, Seidler T, Troughton RW, Yandle TG, Frampton CM, Richards M, . Vigorous response in plasma N-terminal pro-brain natriuretic peptide (NT-BNP) to acute myocardial infarction. Clin Sci. 2004;106:135–9.
   PubMedGoogle Scholar
• de Lemos JA, Morrow DA, Bentley JH, Omland T, Sabatine MS, McCabe CH, . The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med. 2001;345:1014–21.
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Morrow DA, de Lemos JA, Gibson CM, Murphy SA, Rifai N, . Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation. 2002;105:1760–3.
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Morrow DA, Higgins LJ, MacGillivray C, Guo W, Bode C, . Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction. Circulation. 2008;117:1936–44.
   PubMed Web of Science ®Google Scholar
• Khan SQ, Narayan H, Ng KH, Dhillon OS, Kelly D, Quinn P, . N-terminal pro-B-type natriuretic peptide complements the GRACE risk score in predicting early and late mortality following acute coronary syndrome. Clin Sci. 2009;117:31–9.
   PubMedGoogle Scholar
• Kragelund C, Gronning B, Kober L, Hildebrandt P, Steffensen R. N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Engl J Med. 2005;352:666–75.
   PubMed Web of Science ®Google Scholar
• Bibbins-Domingo K, Gupta R, Na B, Wu AHB, Schiller NB, Whooley MA. N-terminal fragment of the prohormone brain-type natriuretic peptide (NT-proBNP), cardiovascular events, and mortality in patients with stable coronary heart disease. JAMA. 2007;297:169–76.
   PubMed Web of Science ®Google Scholar
• Omland T, Sabatine MS, Jablonski KA, Rice MM, Hsia J, Wergeland R, . Prognostic value of B-type natriuretic peptides in patients with stable coronary artery disease: the PEACE Trial. J Am Coll Cardiol. 2007;50:205–14.
   PubMed Web of Science ®Google Scholar
• Staub D, Nusbaumer C, Zellweger MJ, Jonas N, Wild D, Pfisterer ME, . Use of B-type natriuretic peptide in the detection of myocardial ischemia. Am Heart J. 2006;151: 1223–30.
   PubMed Web of Science ®Google Scholar
• Sanchis J, Bosch X, Bodí V, Núñez J, Doltra A, Heras M, . Randomized comparison between clinical evaluation plus N-terminal pro-B-type natriuretic peptide versus exercise testing for decision making in acute chest pain of uncertain origin. Am Heart J. 2010;159:176–82.
   Google Scholar
• Hawkridge AM, Heublein DM, Bergen HR, Cataliotti A, Burnett JC, Muddiman DC. Quantitative mass spectral evidence for the absence of circulating brain natriuretic peptide (BNP-32) in severe human heart failure. Proc Natl Acad Sci U S A. 2005;102:17442–7.
   PubMed Web of Science ®Google Scholar
• Niederkofler EE, Kiernan UA, O'Rear J, Menon S, Saghir S, Protter AA, . Detection of endogenous B-type natriuretic peptide at very low concentrations in patients with heart failure. Circ Heart Fail. 2008;1:258–64.
   PubMed Web of Science ®Google Scholar
• Lainchbury JG, Richards AM, Nicholls MG, Hunt PJ, Ikram H, Espiner EA, . The effects of pathophysiological increments in brain natriuretic peptide in left ventricular systolic dysfunction. Hypertension. 1997;30:398–404.
   PubMed Web of Science ®Google Scholar
• Colucci WS, Elkayam U, Horton DP, Abraham WT, Bourge RC, Johnson AD, . Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. N Engl J Med. 2000;343:246–53.
   PubMed Web of Science ®Google Scholar
• Topol EJ. Nesiritide—not verified. N Engl J Med. 2005; 353:113–6.
   PubMed Web of Science ®Google Scholar
• Nakanishi M, Saito Y, Kishimoto I, Harada M, Kuwahara K, Takahashi N, . Role of natriuretic peptide receptor guanylyl cyclase-A in myocardial infarction evaluated using genetically engineered mice. Hypertension. 2005;46:441–7.
   PubMed Web of Science ®Google Scholar
• Hillock RJ, Frampton CM, Yandle TG, Troughton RW, Lainchbury JG, Richards AM. B-type natriuretic peptide infusions in acute myocardial infarction. Heart. 2008;94:617–22.
   Google Scholar
• Chen HH, Martin FL, Gibbons RJ, Schirger JA, Wright RS, Schears RM, . Low-dose nesiritide in human anterior myocardial infarction suppresses aldosterone and preserves ventricular function and structure: a proof of concept study. Heart. 2009;95:1315–9.
   Google Scholar
• Kitakaze M, Asakura M, Kim J, Shintani Y, Asanuma H, Hamasaki T, . Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials. Lancet. 2007;370:1483–93.
   PubMed Web of Science ®Google Scholar
• Lisy O, Huntley BK, McCormick DJ, Kurlansky PA, Burnett JC Jr. Design, synthesis, and actions of a novel chimeric natriuretic peptide: CD-NP. J Am Coll Cardiol. 2008;52:60–8.
   Google Scholar
• Pan S, Chen HH, Dickey DM, Boerrigter G, Lee C, Kleppe LS, . Biodesign of a renal-protective peptide based on alternative splicing of B-type natriuretic peptide. Proc Natl Acad Sci U S A. 2009;106:11282–7.
   Google Scholar
• Cataliotti A, Schirger JA, Martin FL, Chen HH, McKie PM, Boerrigter G, . Oral human brain natriuretic peptide activates cyclic guanosine 3′,5′-monophosphate and decreases mean arterial pressure. Circulation. 2005;112:836–40.
   PubMed Web of Science ®Google Scholar
• Therrien J-P, Kim SM, Terunuma A, Qin Y, Tock CL, Pfützner W, . A gene therapy approach for long-term normalization of blood pressure in hypertensive mice by ANP-secreting human skin grafts. Proc Natl Acad Sci U S A. 2010;107:1178–83.
   PubMed Web of Science ®Google Scholar
• Ruilope LM, Dukat A, Bohm M, Lacourciere Y, Gong J, Lefkowitz MP. Blood- pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin 11 receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet. 2010;375:1255–66.
   PubMed Web of Science ®Google Scholar
• Siriwardena M, Kleffmann T, Ruygrok P, Cameron VA, Yandle TG, Nicholls MG, . B-type natriuretic peptide signal peptide circulates in human blood. Circulation. 2010; 122:255–64.
   Google Scholar